×

New Data From Epratuzumab to be Presented at EULAR 2013

MORRIS PLAINS, N.J., June 10, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that Immunomedics and UCB (Euronext Brussels:UCB), a global biopharmaceutical company with a focus on immunology treatment and research, will present new data for their investigational studies of epratuzumab in systemic lupus erythematosus (SLE) at the European League Against Rheumatism (EULAR) 2013 Congress to be held in Madrid, Spain, from June 12 – 15, 2013.

Epratuzumab is an investigational medicine in development for the treatment of SLE. It is the first monoclonal antibody targeting CD22, a B-cell-specific protein that regulates B-cell activity.1,2 Epratuzumab is not licensed in SLE.

Following is a guide to the investigational studies of epratuzumab for SLE being presented as oral presentations or posters at EULAR.

1. [OP0118]: Epratuzumab Mediates BCR-Antigen Trogocytosis As Potential Mechanism Of Action In Systemic Lupus Erythematosus (SLE)
Goldenberg, D. et al.

  • Date/Time: June 13, 2013; 1120; Room N118
  • Session Info: Oral, Scientific Session

2. [THU0045]: Epratuzumab, An Antibody Targeting CD22 On B Cells, Induces Phosphoprotein Changes Following B-Cell Receptor Activation In Vitro
Lumb, S. et al.

  • Date/Time: June 13, 2013; 1145-1330
  • Session Info: Poster Tour, Poster Area

3. [THU0277]: Epratuzumab: Sustained Safety Profile And Effect On Corticosteroid Use On Long-Term Treatment In Patients With Moderate-To-Severe Systemic Lupus Erythematosus: Results From An Open-Label Long-Term Extension Study (SL0008)
Wallace, D. et al.

  • Date/Time: June 13, 2013; 1145-1330
  • Session Info: Poster Session, Poster Area

4. [THU0272]: Epratuzumab Maintains Improvements In Disease Activity For Over 2 Years In Patients With Moderate-To-Severe Systemic Lupus Erythematosus: Results From An Open-Label Long-Term Extension Study (SL0008)
Gordon, C. et al.

  • Date/Time: June 13, 2013; 1145-1330
  • Session Info: Poster Session, Poster Area

5. [THU0286]: Immunologic Response To Long-Term Epratuzumab Treatment In SL0008, An Open-Label Longterm Extension Study In Patients With Moderate-To-Severe Systemic Lupus Erythematosus
Strand, V. et al.

  • Date/Time: June 13, 2013; 1145-1330
  • Session Info: Poster Session, Poster Area

6. [THU0029]: Epratuzumab Influences BCR Signalling On TLR9 Pre-Activated B Cells By Targeting CD22
Sieger, N. et al.

  • Date/Time: June 13, 2013; 1145-1330
  • Session Info: Poster Session, Poster Area

References

1. Sanz I., Eun-Hyung Lee F. B cells as therapeutic targets in SLE. Rheumatology; Vol. 6. 2010; Pp 326-327.

2. Walker J., Smith K. B cells as therapeutic targets in SLE. Immunology; Vol. 123. 2008; Pp 314-325.

About Immunomedics

Immunomedics is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. We also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a novel DOCK-AND-LOCK™ (DNL™) method with us for making fusion proteins and multifunctional antibodies, and a new method of delivering imaging and therapeutic agents selectively to disease, especially different solid cancers (colorectal, lung, pancreas, etc.), by proprietary, antibody-based, pretargeting methods. We believe that our portfolio of intellectual property, which includes approximately 223 active patents in the United States and more than 400 foreign patents, protects our product candidates and technologies. Our strength in intellectual property has resulted in the top-10 ranking in the 2012 IEEE Spectrum Patent Power Scorecards in the Biotechnology and Pharmaceuticals category. For additional information on us, please visit our website at www.immunomedics.com. The information on our website does not, however, form a part of this press release.

This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials, out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, potential collaborations, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with any cash payment that the Company might receive in connection with a sublicense involving a third party and UCB, which is not within the Company's control, new product development (including clinical trials outcome and regulatory requirements/actions), our dependence on our licensing partners for the further development of epratuzumab and veltuzumab for non-cancer indications, competitive risks to marketed products and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: For More Information: Dr. Chau Cheng Senior Director, Investor Relations & Grant Management (973) 605-8200, extension 123 ccheng@immunomedics.comSource:Immunomedics, Inc.